Vitae surges after reporting psoriasis data
Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) rose $2.68 (65%) to $6.79 on Thursday after reporting data from 34 psoriasis patients in a Phase I/II trial of VTP-43742, and disclosing that it plans to start a larger, 16-week Phase II trial of the compound by YE16. VTP-43742 is an oral small molecule inhibitor of RAR-related orphan receptor C thymus-specific isoform ( RORgamma2; RORgammaT).
In the four-week Phase IIa portion of the trial, patients receiving 350 mg of VTP-43742 daily had a 24% reduction from baseline relative to placebo in Psoriasis Area Severity Index (PASI) score at day 28 (p=0.015), while patients receiving 700 mg had a 30% placebo-adjusted reduction (p=0.003). Vitae said the rate of reduction accelerated during the second half of the treatment period for both doses, suggesting potential for greater efficacy with longer duration of treatment. ...